In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, ...
In patients with atrial fibrillation (A-fib) who cannot take warfarin, the oral factor Xa inhibitor apixaban produces a rate of major bleeding in line with that of aspirin. Bleeding events with the 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback